Ketorolac tromethamine formulations: An overview

Expert Opinion on Drug Delivery

Volumn 6, Issue 9, 2009, Pages 961-975

  Sinha, V R ^a   Kumar, R V ^a   Singh, G ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Gels; Intraoral; Ketorolac tromethamine; Nasal; Ocular; Ointments; Oral; Parenteral; Transdermal

Indexed keywords

ACULAR LS; CORTICOSTEROID; DICLOFENAC; EUDRAGIT; EXODOL; KETOROLAC; KETOROLAC TROMETAMOL; NEPAFENAC; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; POLYCAPROLACTONE; POLYGLACTIN; RESOMER; STEROID; UNCLASSIFIED DRUG;

ALLERGIC CONJUNCTIVITIS; AREA UNDER THE CURVE; CHRONIC PAIN; COST EFFECTIVENESS ANALYSIS; DIGESTIVE SYSTEM PERFORATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG POTENCY; DRUG RELEASE; DRUG SAFETY; DRUG STABILITY; DRUG STRUCTURE; DRUG TOLERABILITY; ENTERIC COATED TABLET; EYE INFLAMMATION; EYE IRRITATION; EYE PAIN; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HUMAN; INFLAMMATION; INJECTION SITE PAIN; KIDNEY INJURY; LABOR PAIN; MAXIMUM PLASMA CONCENTRATION; MIGRAINE; MIOSIS; MUSCULOSKELETAL PAIN; NONHUMAN; PAIN; PATIENT COMPLIANCE; PEPTIC ULCER; PLASMA HALF LIFE; POSTMARKETING SURVEILLANCE; POSTOPERATIVE INFLAMMATION; POSTOPERATIVE PAIN; POSTPARTUM PAIN; POSTTRAUMATIC PAIN; REVIEW; SUSTAINED RELEASE FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; DELAYED-ACTION PREPARATIONS; GASTROINTESTINAL DISEASES; HALF-LIFE; HUMANS; KETOROLAC TROMETHAMINE; STEREOISOMERISM;

EID: 70249103169     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425240903116006     Document Type: Review

References (103)

1. Gilman G. The pharmacological basis of therapeutics. 10th edition: McGraw-Hill Medical Publishing Division; 2001
2. Muchowski JM, Kluge AF, inventors; Syntex (USA), Inc, assignee. 5-Aroyl-1, 2-dihydro-3H-pyrrolo [1, 2-a] pyrrole-1-carboxylic acid derivatives and process for the production thereof. US4089969; 1978
3. Guzman A, Yuste F, Toscano RA, et al. Absolute configuration of (-)-5-benzoyl-1,2-dihydro-3H-pyrrolo [1,2-alpha]pyrrole-1-carboxylic acid, the active enantiomer of ketorolac. J Med Chem 1986;29(4):589-591
4. Mroszczak E, Combs D, Chaplin M, et al. Chiral kinetics and dynamics of ketorolac. J Clin Pharmacol 1996;36(6):521-539
5. Orange book. Available from: http://www.fda.gov/cder/ob/
6. Electronic medicines compendia. Available from: http://emc.medicines.org. uk/
7. Physician desk reference. 54th edition; 2000
8. Rooks W, Tomolonis AJ, Maloney PJ, et al. The analgesic and anti-inflammatory profile of (+/-)-5-benzoyl-1,2-dihydro-3Hpyrrolo[ 1,2a]pyrrole-1-carboxylic acid (RS-37619). Agents Actions 1982;12:684-690
9. Conrad KA, Fagan TC, Mackie MJ, Mayshar PV. Effects of ketorolac tromethamine on hemostasis in volunteers. Clin Pharmacol Ther 1988;43(5):542-546
10. Spowart KGI, Mclaren M, Lloyd J, et al. Haemostatic effects of ketorolac with and without concomitant heparin in normal volunteers. Thromb Haemost 1988;60:382-386 (Pubitemid 19023727)
11. Buckley MM, Brogden RN. Ketorolac. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 1990;39(1):86-109
12. Chow GK, Fabrizio MD, Steer T, et al. Prospective double-blind study of effect of ketorolac administration after laparoscopic urologic surgery. J Endourol 2001;15(2):171-174 (Pubitemid 32290838)
13. Schoneboom B. Ketorolac tromethamine: a nonsteroidal anti-inflammatory analgesic used as an adjunct for general anesthesia. AANA J 1992;60(3):304-307
14. Di Trolio R, Sing RF, Bates GM. Use of ketorolac in renal colic. J Am Osteopath Assoc 1999;99(11):589-590
15. Carlson RW, Borrison RA, Sher HB, et al. A multiinstitutional evaluation of the analgesic efficacy and safety of ketorolac tromethamine, acetaminophen plus codeine, and placebo in cancer pain. Pharmacotherapy 1990;10(3):211-216
16. Litvak KM, McEvoy GK. Ketorolac, an injectable nonnarcotic analgesic. Clin Pharm 1990;9(12):921-935
17. Anthony D, Jasinski DM. Postoperative pain management: morphine versus ketorolac. J Perianesth Nurs 2002;17(1):30-42 (Pubitemid 40433789)
18. Arsac M, Frileux C. Comparative analgesic efficacy and tolerability of ketorolac tromethamine and glafenine in patients with post-operative pain. Curr Med Res Opin 1988;11(4):214-220 (Pubitemid 19009457)
19. Thagaard KS, Jensen HH, Raeder J. Analgesic and antiemetic effect of ketorolac vs. betamethasone or dexamethasone after ambulatory surgery. Acta Anaesthesiol Scand 2007;51(3):271-277 (Pubitemid 46271103)
20. Burd RS, Tobias JD. Ketorolac for pain management after abdominal surgical procedures in infants. South Med J 2002;95(3):331-333
21. Papacci PDFG, Iacobucci T, Giannantonio C, et al. Use of intravenous ketorolac in the neonate and premature babies. Paediatr Anaesth 2004;14:487-492 (Pubitemid 38758669)
22. Lynn A, Bradford H, Kantor ED, et al. Postoperative ketorolac tromethamine use in infants aged 6-18 months: the effect on morphine usage, safety assessment, and stereo-specific pharmacokinetics. Anesth Analg 2007;104(5):1040-1051 (Pubitemid 46649920)
23. Diblasio CJ, Snyder ME, Kattan MW, Russo P. Ketorolac: safe and effective analgesia for the management of renal cortical tumors with partial nephrectomy. J Urol 2004;171(3):1062-1065 (Pubitemid 38327527)
24. Yalcin S, Gullu I, Tekuzman G, Savas C. Ketorolac tromethamine in cancer pain. Acta Oncol 1997;36(2):231-232
25. Fraser-Smith EB, Matthews TR. Effect of ketorolac on Pseudomonas aeruginosa ocular infection in rabbits. J Ocul Pharmacol 1988 Summer;4(2):101-109 (Pubitemid 18187949)
26. Baevsky RH, Nyquist SN, Roy MN, Smithline HA. Antipyretic effectiveness of intravenous ketorolac tromethamine. J Emerg Med 2004;26(4):407-410
27. Brown CR, Moodie JE, Dickie G, et al. Analgesic efficacy and safety of single-dose oral and intramuscular ketorolac tromethamine for postoperative pain. Pharmacotherapy 1990;10(6(Pt 2)):59S-70S
28. Yee JP, Koshiver JE, Allbon C, Brown CR. Comparison of intramuscular ketorolac tromethamine and morphine sulfate for analgesia of pain after major surgery. Pharmacotherapy 1986;6(5):253-261 (Pubitemid 17180616)
29. Kostrzewa D. Is ketorolac more cost-effective? Am J Hosp Pharm 1991;48:2128-2129
30. Jung D, Mroszczak EJ, Wu A, et al. Pharmacokinetics of ketorolac and p-hydroxyketorolac following oral and intramuscular administration of ketorolac tromethamine. Pharm Res 1989;6(1):62-65 (Pubitemid 19060825)
31. Mroszczak EJ, Lee FW, Combs D, et al. Ketorolac tromethamine absorption, distribution, metabolism, excretion, and pharmacokinetics in animals and humans. Drug Metab Dispos 1987;15(5):618-626 (Pubitemid 18004616)
32. The merck index. 13th edition; Merck & Co., Inc. Whitehouse station, NJ. 1998
33. USP NF. 27th edition; United States Pharmacopoeial Convention, INC. 12601 Twinbrook Parkway, Rockville, MD20852. 2004
34. Kamath BV, Shivram K, Shah AC. Determination of diclofenac sodium, famotidine and ketorolac tromethamine by flow injection analysis using dichloronitrophenol. J Pharm Biomed Anal 1994;12(3):343-346 (Pubitemid 24151959)
35. Devarajan PV, Gore SP, Chavan SV. HPTLC determination of ketorolac tromethamine. J Pharm Biomed Anal 2000;22(4):679-683
36. Eid M, El-Brashy A, Aly F, Talaat W. Spectrofluorometric determination of ketorolac tromethamine via its oxidation with cerium(IV) in pharmaceutical preparations and biological fluids. J AOAC Int 2007;90(4):941-947 (Pubitemid 47266047)
37. Santhosh P, Senthil Kumar N, Renukadevi M, et al. Enhanced electrochemical detection of ketorolac tromethamine at polypyrrole modified glassy carbon electrode. Anal Sci 2007;23(4):475-478
38. Fries JF, Williams CA, Bloch DA, Michel BA. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med 1991;91(3):213-222
39. Davies PH, Stewart SE, Lancranjan L, et al. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly. Clin Endocrinol (Oxf ) 1998;48(3):311-316
40. Genc L, Jalvand E. Preparation and in vitro evaluation of controlled release hydrophilic matrix tablets of ketorolac tromethamine using factorial design. Drug Dev Ind Pharm 2008;34(8):903-910
41. Genc A, Guler AE, Hegazy N. Film-coated enteric tablet formulation of ketorolac tromethamine. Drug Dev Ind Pharm 1997;23(10):1007-1010 (Pubitemid 27412608)
42. Arora R, Srivastava AK, Rani M, Mishra B. Investigations on osmotic matrix tablets as controlled delivery systems of ketorolac tromethamine. Acta Pharm Turcica 2002;44:87-96 (Pubitemid 36287789)
43. Vatsaraj N, Zia H, Needham T. Formulation and optimization of a sustained-release tablet of ketorolac tromethamine. Drug Deliv 2002;9(3):153-159 (Pubitemid 34898938)
44. Ruckmani K, Muneera MS, Vijaya R. Eudragit matrices for sustained release of ketorolac tromethamine: formulation and kinetics of release. Boll Chim Farm 2000;139(5):205-208 (Pubitemid 32107841)
45. Rahman B, Rahman MM, Ahmed M, et al. Development and evaluate the formulation of ketorolac tromethamine tablets and a comparative study with marketed product. Res J Med Med Sci 2007;2(2):102-105
46. Genc L, Demirel M, Guler E, Hegazy N. Microencapsulation of ketorolac tromethamine by means of a coacervation-phase separation technique induced by the addition of non-solvent. J Microencapsul 1998;15(1):45-53 (Pubitemid 28031789)
47. Etman M, Nada H, Nada A, et al. Formulation of sustained-release ketorolac tromethamine pellets. Pharm Technol 2008;32(12):58-61
48. Lee F-Y, Chen S-C, Chen P-K, Kuo H-C, inventor Yung Shin Pharmaceutical Industrial Co., Ltd., assignee. Oral pharmaceutical compositions containing non-steroidal anti-inflammatory drugs and method for preparing the same. US6902746; 2002
49. Robinson JR, McGinity JW, Delmas P, inventors; Ethypharm, assignee. Effervescent granules and methods for their preparation. US6649186; 2003
50. Gordon MS, Ling TL, Yee JP. Ketorolac tromethamine bioavailability via tablet, capsule, and oral solution dosage forms. Drug Dev Ind Pharm 1995;21(10):1143-1155
51. Gordon MS, Chowhan Z. In vivo/in vitro correlations for four differently dissolving ketorolac tablets. Biopharm Drug Dispos 1996;17(6):481-492
52. Flores-Murrieta FJ, Granados-Soto V, Castaneda-Hernandez G, et al. Comparative bioavailability of two oral formulations of ketorolac tromethamine: Dolac and Exodol. Biopharm Drug Dispos 1994;15(2):129-136 (Pubitemid 24089059)
53. Bhaskaran S, Suresh S. Biodegradable microspheres of ketorolac tromethamine for parenteral administration. J Microencapsul 2004;21(7):743-750 (Pubitemid 40100601)
54. Sinha VR, Trehan A. Formulation, characterization, and evaluation of ketorolac tromethamine-loaded biodegradable microspheres. Drug Deliv 2005;12(3):133-139 (Pubitemid 40604992)
55. Sinha VR, Trehan A. Development, characterization, and evaluation of ketorolac tromethamine-loaded biodegradable microspheres as a depot system for parenteral delivery. Drug Deliv 2008;15(6):365-372
56. Mathew ST, Devi SG, Kv S. Formulation and evaluation of ketorolac tromethamine-loaded albumin microspheres for potential intramuscular administration. AAPS PharmSciTech 2007;8(1):14
57. Puri V, Bansal AK. In vitro-in vivo characterization of release modifying agents for parenteral sustained-release ketorolac formulation. Drug Dev Ind Pharm 2004;30(6):619-626
58. Alsarra IA, Bosela AA, Ahmed SM, Mahrous GM. Proniosomes as a drug carrier for transdermal delivery of ketorolac. Eur J Pharm Biopharm 2005;59(3):485-490 (Pubitemid 40342523)
59. Lichtenberger L, Dial EJ, inventor. The board of regents of the University of Texas System, assignee. Parenteral preparations of GI-safer phospholipid-associated anti-inflammatories and methods of preparation and use. US20080051373; 2008
60. Lee F-Y, Chen Shang-Chiung, Chin Heikon, Keinyo S, inventors; Yung Shin Pharm Ind Co Ltd., assignee. Injectable pharmaceutical composition containing non-steroidal anti-inflammatory drug and method for preparing the same. JP2003300905; 2003
61. Schechter B. Ketorolac tromethamine 0.4% as a treatment for allergic conjuctivitis. Expert Opin Drug Metab Toxicol 2008;4(4):507-511 (Pubitemid 351728522)
62. Trattler W, McDonald M. Double-masked comparison of ketorolac tromethamine 0.4% versus nepafenac sodium 0.1% for postoperative healing rates and pain control in eyes undergoing surface ablation. Cornea 2007;26(6):665-669 (Pubitemid 47080282)
63. Sandoval HP, De Castro LE, Vroman DT, Solomon KD. Evaluation of 0.4% ketorolac tromethamine ophthalmic solution versus 0.5% ketorolac tromethamine ophthalmic solution after phacoemulsification and intraocular lens implantation. J Ocul Pharmacol Ther 2006;22(4):251-257
64. Goguen ER, Roberts CW. Topical NSAIDS to control pain in clear corneal cataract extraction. Insight 2004;29(3):10-11 (Pubitemid 39419661)
65. Heier J, Cheetham JK, Degryse R, et al. Ketorolac tromethamine 0.5% ophthalmic solution in the treatment of moderate to severe ocular inflammation after cataract surgery: a randomized, vehicle-controlled clinical trial. Am J Ophthalmol 1999;127(3):253-259 (Pubitemid 29128121)
66. Schalnus R. Topical nonsteroidal anti-inflammatory therapy in ophthalmology. Ophthalmologica 2003;217(2):89-98 (Pubitemid 36237702)
67. Solomon KD, Vroman DT, Barker D, Gehlken J. Comparison of ketorolac tromethamine 0.5% and rimexolone 1% to control inflammation after cataract extraction. Prospective randomized double-masked study. J Cataract Refract Surg 2001;27(8):1232-1237 (Pubitemid 32771355)
68. Snyder R, Siekert RW, Schwiegerling J, et al. Acular as a single agent for use as an antimiotic and anti-inflammatory in cataract surgery. J Cataract Refract Surg 2000;26(8):1225-1227 (Pubitemid 30727678)
69. Simone JN, Pendelton RA, Jenkins JE. Comparison of the efficacy and safety of ketorolac tromethamine 0.5% and prednisolone acetate 1% after cataract surgery. J Cataract Refract Surg 1999;25(5):699-704 (Pubitemid 29222602)
70. Sitenga GL, Ing EB, Van Dellen RG, et al. Asthma caused by topical application of ketorolac. Ophthalmology 1996;103(6):890-892
71. Fu CCR, Lidgate DM, inventors; Syntex (USA), Inc., assignee. Preservative system for ophthalmic formulations. US5414011; 1995
72. Malhotra M, Majumdar DK. In vitro transcorneal permeation of ketorolac from oil based ocular drops and ophthalmic ointment. Indian J Exp Biol 1997;35(12):1324-1330
73. Malhotra M, Majumdar DK. In vivo ocular availability of ketorolac following ocular instillations of aqueous, oil, and ointment formulations to normal corneas of rabbits: a technical note. AAPS PharmSciTech 2005;6(3):E523-6
74. Malhotra M, Majumdar DK. Aqueous, oil, and ointment formulations of ketorolac: efficacy against prostaglandin E2-induced ocular inflammation and safety: a technical note. AAPS PharmSciTech 2006;7(4):96 (Pubitemid 46296473)
75. Ousler G, Chapin MJ, Abelson MB, inventors; Ophthalmic Research Associates, Inc., assignee. Formulations and methods for treating dry eye. WO07087609; 2007
76. Karataş A, Baykara T. Studies on release of ketorolac tromethamine and indomethacin from ophthalmic hydrogel inserts. J Fac Pharm Ankara 2006;35(4):255-268 (Pubitemid 350228852)
77. Muller C, Cheetham JK, Kuan TH, Power DF, inventor Allergan, Inc., assignee. Ketorolac tromethamine compositions for treating or preventing ocular pain. US20080027120; 2008
78. Sankar C, Mishra B. Development and in vitro evaluations of gelatin A microspheres of ketorolac tromethamine for intranasal administration. Acta Pharm 2003;53(2):101-110 (Pubitemid 36850881)
79. Zia H, Needham TE, Quadir M, inventor. The board of Governors for Higher Education, State of Rhode Island and providence plantations, assignee. Pharmaceutical compositions for intranasal spray administration of ketorolac tromethamine US6090368; 2000
80. Whiting R, Thirucote W, inventors; Roxro Pharma, Inc., assignee. Therapeutic compositions for intranasal administration of ketorolac. WO06071601; 2006
81. Santus G, Bottoni G, Bilato E, inventor Recordati SA. Chemical and Pharmaceutical Company, assignee. Therapeutic compositions for intranasal administration which include Ketorolac. US6333044; 2001
82. Quadir M, Zia H, Needham TE. Development and evaluation of nasal formulations of ketorolac. Drug Deliv 2000;7(4):223-229 (Pubitemid 32057554)
83. Cavanaugh J, Paul F, inventor The Procter & Gamble Company, assignee. Use of ketorolac for treatment of squamous cell carcinomas of the oral cavity or oropharynx. USRE36419; 1999
84. Kelm GR, Buchanan W, Meredith MP, et al. Evaluation of ketorolac concentrations in plasma and gingival crevicular fluid following topical treatment with oral rinses and dentifrices. J Pharm Sci 1996;85(8):842-847 (Pubitemid 26269479)
85. Alanazi F, Abdel Rahman AA, Mahrous GM, Alsarra IA. Formulation and physicochemical characterization of buccoadhesive films containing ketorolac. J Drug Del Sci Tech 2007;17(1):1-10 (Pubitemid 47057011)
86. Cho YA, Gwak HS. Transdermal delivery of ketorolac tromethamine: effects of vehicles and penetration enhancers. Drug Dev Ind Pharm 2004;30(6):557-564 (Pubitemid 38924625)
87. Venkateshwaran S, Fikstad D, Ebert CD, inventors; Watson Pharmaceutical, Inc., assignee. Method of making pressure sensitive adhesive matrix patches for transdermal drug delivery using hydrophilic salts of drugs and hydrophobic pressure sensitive adhesive dispersions. US6365178; 2002
88. Choi JS, Cho YA, Chun IK, et al. Formulation and evaluation of ketorolac transdermal systems. Drug Deliv 2007;14(2):69-74
89. Uhrich K, Schmalenberg K, inventors; Rutgers, The State University, assignee. Therapeutic devices for patterned cell growth. WO04006863; 2004
90. Kim Y, Choi YG, Kim JJ, inventor Pacific Corprtn., assignee. Film-forming agent for drug delivery and preparation for percutaneous administration containing the same. US6750291; 2001
91. Miller K, Sydney GT, Geitz K, Dayton PL, Sahatjian RA, inventor Boston Scientific Scimed, Inc., assignee. Implantable or insertable medical device resistant to microbial growth and biofilm formation. US6887270; 2005
92. Lee W, Lee YD, Kim JJ, inventors; Pacific Corprtn, assignee. Transdermal preparation containing hydrophilic or salt-form drug. EP1163902B1; 2007
93. Wong O, Nguyen TN, inventors; CYGNUS, Inc., assignee. Monolithic matrix transdermal delivery system for delivering ketorolac tromethamine. US5804214; 1998
94. Ruozi B, Tosi G, Forni F, Angela Vandelli M. Ketorolac tromethamine liposomes: encapsulation and release studies. J Liposome Res 2005;15(3-4):175-185 (Pubitemid 43062266)
95. Devaraj GN, Parakh SR, Devraj R, et al. Release studies on niosomes containing fatty alcohols as bilayer stabilizers instead of cholesterol. J Colloid Interface Sci 2002;251(2):360-365 (Pubitemid 34775403)
96. Nasseri A, Aboofazeli R, Zia H, Needham TE. Lecithin stabilized microemulsion: An organogel for topical application of Ketorolac tromethamine. I: phase behavior studies. Iran J Pharm Res 2003;2:59-63
97. Nasseri A, Aboofazeli R, Zia H, Needham TE. Lecithin - stabilized microemulsion - based organogels for topical application of ketorolac tromethamine. II. In vitro Release Study. Iran J Pharm Res 2003;117-123
98. Ong J, Fujiki JS, Liaw Wei-Cheng, inventor Syntex (USA), Inc., assignee. Dispensing units for ketorolac topical gel formlations. US5091182; 1992
99. Tiwari SB, Pai RM, Udupa N. Influence of ultrasound on the percutaneous absorption of ketorolac tromethamine in vitro across rat skin. Drug Deliv 2004;11(1):47-51 (Pubitemid 38292727)
100. Yang JH, Kim TY, Lee JH, et al. Anti-hyperalgesic and anti-inflammatory effects of ketorolac tromethamine gel using pulsed ultrasound in inflamed rats. Arch Pharm Res 2008;31(4):511-517
101. Yang JH, Yun MY, Kim DK, et al. Preparation and evaluation of ketorolac tromethamine gel containing genipin for periodontal diseases. Arch Pharm Res 2007;30(7):871-875
102. Yang JH, Yun MY, Lee NH, et al. The effects of ketorolac tromethamine and baicalein on the levels of inflammatory factors in human synoviocytes. Arch Pharm Res 2008;31(11):1517-1523
103. Gupta SK, Sathyan G, Padmanabhan R, inventors; Alza Corporation, assignee. Stereospecific delivery of a drug using electrotransport. US6136327; 2000